Published in J Mol Med (Berl) on March 16, 2012
CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res (2013) 1.48
CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to erlotinib via transcriptional regulation of EGFR. Mol Cancer (2014) 1.06
Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol (2012) 1.01
Prostate cancer research in China. Asian J Androl (2013) 0.96
CUL4A ubiquitin ligase: a promising drug target for cancer and other human diseases. Open Biol (2014) 0.92
Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. Acta Biochim Biophys Sin (Shanghai) (2013) 0.88
Lung tumourigenesis in a conditional Cul4A transgenic mouse model. J Pathol (2014) 0.86
CUL4A contributes to the biology of basal-like breast tumors through modulation of cell growth and antitumor immune response. Oncotarget (2014) 0.85
Regulated in development and DNA damage responses -1 (REDD1) protein contributes to insulin signaling pathway in adipocytes. PLoS One (2012) 0.83
From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma. Cancer Cell (2014) 0.82
The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications. Oncotarget (2015) 0.80
Distinct and overlapping functions of the cullin E3 ligase scaffolding proteins CUL4A and CUL4B. Gene (2015) 0.79
Recurrent Amplification at 13q34 Targets at CUL4A, IRS2, and TFDP1 As an Independent Adverse Prognosticator in Intrahepatic Cholangiocarcinoma. PLoS One (2015) 0.77
Dysregulation of CUL4A and CUL4B Ubiquitin Ligases in Lung Cancer. J Biol Chem (2016) 0.76
Knockdown of CUL4B inhibits proliferation and promotes apoptosis of colorectal cancer cells through suppressing the Wnt/β-catenin signaling pathway. Int J Clin Exp Pathol (2015) 0.76
Cullin 4A is associated with epithelial to mesenchymal transition and poor prognosis in perihilar cholangiocarcinoma. World J Gastroenterol (2017) 0.75
CUL4A promotes proliferation and metastasis of colorectal cancer cells by regulating H3K4 trimethylation in epithelial-mesenchymal transition. Onco Targets Ther (2017) 0.75
CUL4A promotes cell invasion in gastric cancer by activating the NF-κB signaling pathway. Biologics (2017) 0.75
miR-181a-2 downregulates the E3 ubiquitin ligase CUL4A transcript and promotes cell proliferation. Med Oncol (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Identification of a primary target of thalidomide teratogenicity. Science (2010) 7.09
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood (2011) 3.58
The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer (2004) 3.58
CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation. Nat Cell Biol (2006) 3.49
Histone H3 and H4 ubiquitylation by the CUL4-DDB-ROC1 ubiquitin ligase facilitates cellular response to DNA damage. Mol Cell (2006) 3.39
Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis (1997) 2.97
CDK inhibitor p21 is degraded by a proliferating cell nuclear antigen-coupled Cul4-DDB1Cdt2 pathway during S phase and after UV irradiation. J Biol Chem (2008) 2.63
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia (2009) 2.50
TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology (2002) 2.05
The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Res (1998) 1.88
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet (2004) 1.80
High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk Lymphoma (2010) 1.58
Cul4A targets p27 for degradation and regulates proliferation, cell cycle exit, and differentiation during erythropoiesis. Blood (2006) 1.43
Cul4A physically associates with MDM2 and participates in the proteolysis of p53. Cancer Res (2004) 1.40
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood (2010) 1.36
Comparative genomic hybridization of squamous cell carcinoma of the esophagus: the possible involvement of the DPI gene in the 13q34 amplicon. Genes Chromosomes Cancer (1999) 1.33
Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. Breast Cancer Res (2009) 1.32
Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer (2000) 1.23
Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated with poor outcome in node-negative breast cancer. Anticancer Res (2007) 1.22
DNA damage binding protein component DDB1 participates in nucleotide excision repair through DDB2 DNA-binding and cullin 4A ubiquitin ligase activity. Cancer Res (2006) 1.21
Cul4A is an oncogene in malignant pleural mesothelioma. J Cell Mol Med (2011) 1.21
Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.16
Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization. J Pediatr Hematol Oncol (2002) 1.12
Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology (2008) 0.87
Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res (2004) 0.86
Lenalidomide down regulates the production of interferon-gamma and the expression of inhibitory cytotoxic receptors of human Natural Killer cells. Cell Immunol (2010) 0.84
Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. Invest New Drugs (2003) 0.81
A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma. Haematologica (2004) 0.78
Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer. Cancer Invest (2010) 0.77
Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols. Urol Oncol (2008) 0.77
Live or let die: the cell's response to p53. Nat Rev Cancer (2002) 15.06
X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006) 7.17
Genome sequencing and analysis of the versatile cell factory Aspergillus niger CBS 513.88. Nat Biotechnol (2007) 6.21
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Total knee arthroplasty volume, utilization, and outcomes among Medicare beneficiaries, 1991-2010. JAMA (2012) 4.89
Improved response to disasters and outbreaks by tracking population movements with mobile phone network data: a post-earthquake geospatial study in Haiti. PLoS Med (2011) 4.38
Availability of consumer prices from US hospitals for a common surgical procedure. JAMA Intern Med (2013) 4.35
Sir2 blocks extreme life-span extension. Cell (2005) 4.25
Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med (2011) 3.84
Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A (2008) 3.71
Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet (2003) 3.70
The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab (2010) 3.61
Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36
Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A (2008) 3.30
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest (2012) 3.14
A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol (2008) 3.13
Clinical characteristics and outcomes of Medicare patients undergoing total hip arthroplasty, 1991-2008. JAMA (2011) 3.09
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res (2007) 3.08
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res (2007) 2.94
Preperitoneal single-port transvesical enucleation of the prostate (STEP) for large-volume BPH: one-year follow-up of Qmax, IPSS, and QoL. Urology (2012) 2.78
PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell (2008) 2.66
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 2.65
Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med (2012) 2.58
Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity (2006) 2.56
Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics (2006) 2.53
Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. Nat Genet (2005) 2.51
Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat (2007) 2.49
iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet (2003) 2.41
RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res (2012) 2.41
Impact of telemedicine intensive care unit coverage on patient outcomes: a systematic review and meta-analysis. Arch Intern Med (2011) 2.41
Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med (2010) 2.32
Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci (2003) 2.29
Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res (2006) 2.29
Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol (2007) 2.23
The ecology, genetic diversity, and phylogeny of Huaiyangshan virus in China. J Virol (2011) 2.23
iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet (2006) 2.20
Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? J Mol Med (Berl) (2005) 2.16
The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol (2007) 2.13
Proteome analysis of laser microdissected glomeruli from formalin-fixed paraffin-embedded kidneys of autopsies of diabetic patients: nephronectin is associated with the development of diabetic glomerulosclerosis. Nephrol Dial Transplant (2011) 2.12
Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med (2009) 2.10
Laparoendoscopic single-site partial nephrectomy: a multi-institutional outcome analysis. Eur Urol (2013) 2.09
XRCC3 T241M polymorphism and bladder cancer risk: a meta-analysis. Urology (2010) 2.08
MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation (2010) 2.07
Genome-wide detection of chromosomal imbalances in tumors using BAC microarrays. Nat Biotechnol (2002) 2.04
CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood (2009) 1.94
Genomic segmental polymorphisms in inbred mouse strains. Nat Genet (2004) 1.93
The association between hospital obstetrical volume and maternal postpartum complications. Am J Obstet Gynecol (2012) 1.90
Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature (2009) 1.89
ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol (2004) 1.88
The microRNA-328 regulates hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type calcium channel-α1C. Hypertension (2012) 1.84
Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood (2007) 1.83
Management of forgotten ureteral stents with holmium laser. Lasers Med Sci (2008) 1.80
The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci U S A (2003) 1.79
A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat Genet (2006) 1.79
Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet (2012) 1.78
Inactivation of hnRNP K by expanded intronic AUUCU repeat induces apoptosis via translocation of PKCdelta to mitochondria in spinocerebellar ataxia 10. PLoS Genet (2010) 1.76
Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell (2012) 1.75
Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer (2013) 1.73
Fasting and cancer treatment in humans: A case series report. Aging (Albany NY) (2009) 1.71
Mapping segmental and sequence variations among laboratory mice using BAC array CGH. Genome Res (2005) 1.71
Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res (2010) 1.71
Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res (2010) 1.69
ASPP2 binds Par-3 and controls the polarity and proliferation of neural progenitors during CNS development. Dev Cell (2010) 1.68
Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut (2010) 1.67
Existence of no hepatocarcinogenic effect levels of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline with or without coadministration with ethanol. Toxicol Pathol (2006) 1.66
Peroxynitrite mediates neurotoxicity of amyloid beta-peptide1-42- and lipopolysaccharide-activated microglia. J Neurosci (2002) 1.66
Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene (2004) 1.64
Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol (2013) 1.64
Genome-wide screen in Saccharomyces cerevisiae identifies vacuolar protein sorting, autophagy, biosynthetic, and tRNA methylation genes involved in life span regulation. PLoS Genet (2010) 1.59
HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc Natl Acad Sci U S A (2007) 1.58
Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res (2013) 1.58
Transcriptional network analysis identifies BACH1 as a master regulator of breast cancer bone metastasis. J Biol Chem (2012) 1.58
Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression. Exp Gerontol (2013) 1.57
Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers (2011) 1.56
Forceps delivery volumes in teaching and nonteaching hospitals: are volumes sufficient for physicians to acquire and maintain competence? Acad Med (2014) 1.55
Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS (2003) 1.55